Yahoo Finance

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 “should be an inflection year” for Rocket with multiple clinical and regulatory catalysts “potentially creating strong momentum” with the shares trading near 52-week lows. Rocket’s RP-A501 for Danon disease has potential to be a $1B commercial opportunity, the analyst tells investors in a research note. The firm thinks an accelerated approval pathway may be possible for RP-A601 in arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene, saying preclinical data from a mouse model show “robust” protein expression, reversal of phenotypes, and near complete rescue of early mortality. Wedbush expects the initial Phase 1 data in the first half of 2025 to show protein expression in cardiomyocytes, which could potentially lead to positive cardiac functional changes that can be detected by lab measures.

Don't Miss Our New Year's Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on RCKT:

• Rocket Pharmaceuticals initiated with an Outperform at Wedbush

• Rocket Pharmaceuticals initiated with a Buy at Jefferies

• Rocket Pharmaceuticals price target lowered to $40 from $44 at Leerink

• Rocket Pharmaceuticals 13.2M share Spot Secondary priced at $12.50

• Closing Bell Movers: Dave & Busters down 11% after Q3 miss